Section Editors

  • Paolo Bruzzi, National Cancer Research Institute
  • Ian Cree, Warwick Medical School, Coventry
  • Shoukat Dedhar, British Columbia Cancer Agency
  • John A Hartley, University College London
  • Manami Inoue, University of Tokyo
  • Ferdinando Mannello, University Carlo Bo
  • Mark McKeage, University of Auckland
  • Christophe Nicot, Kansas University Medical Center
  • Stephen P Povoski, The Ohio State University
  • Charles Rosser, University of Hawaii Cancer Center
  • Dirk Vordermark, Martin Luther University Halle-Wittenberg

Executive Editor

  • Dafne Solera, BioMed Central

Articles

There has been an error retrieving the data. Please try again.
  • Image attributed to: From Figure 3b, BMC Cancer 2014, 14:189

    Nanoscale chromatin changes preceed cancer

    Changes in chromatin density and heterochromatin structure that occur very early during carcinogenesis can be detected and measured by transmission electron microscopy and may lead to the establishment of new biomarkers.

    BMC Cancer 2014, 14:189
  • Image attributed to: CC sharonang pixabay

    PUFAs intake affects cancer risk

    A meta-analysis of published studies confirms that higher intake ratio of n-3/n-6 polyunsaturated fatty acids (PUFAs), found in oily fish, vegetable oils and seeds, is associated with lower risk of breast cancer.

    BMC Cancer 2014, 14:105
  • Image attributed to: Figure 2 BMC Cancer 2014, 14:64

    Immune genes down-regulated in CRC metastasis

    A novel algorithm identifies a set of gene expression markers, related to the MHC class II complex involved in immune response, that could predict the development of metastasis in colorectal carcinoma (CRC) patients.

    BMC Cancer 2014, 14:64
  • Image attributed to: From Figure 5D BMC Cancer 2013, 13:585

    Role of EWS/WT1 isoforms in DSRCT

    The oncogenic potential of two isoforms of the fusion protein EWS/WT1, which characterizes  the rare but deadly desmoplastic small round cell tumor (DSRCT), depends on the loss of p53 in a  murine embryonic fibroblast model.

    BMC Cancer 2013, 13:585
  • Image attributed to: From wikimedia commons, by Taranatha

    Interaction of Ca/Mg with oxaliplatin

    A double blind crossover randomized clinical trial shows that Calcium and Magnesium (Ca/Mg) infusion in colorectal cancer patients does not alter the clinical pharmacokinetics of oxaliplatin, but it also fails to reduce acute its neurotoxicity.

    BMC Cancer 2013, 13:495

Scope

BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.

It is journal policy to publish work deemed by peer reviewers to be a coherent and sound addition to scientific knowledge and to put less emphasis on interest levels, provided that the research constitutes a useful contribution to the field.

Join the Editorial Board!

Are you interested in becoming an Editorial Board member for BMC Cancer and helping to maintain the editorial standards and ethos of this growing journal? To volunteer as an Associate Editor, please simply contact us at bmccancer@biomedcentral.com, enclosing a summary of your research interests and relevant expertise. We look forward to hearing from you.

Latest review

Review

Functional significance of erythropoietin in renal cell carcinoma

Christudas Morais, David W Johnson, David A Vesey, and Glenda C Gobe1

BMC Cancer 2013, 13:14 (10 January 2013)

Section Editor's profile

Mark McKeage

Mark McKeage is a medical oncologist and associate professor in the department of pharmacology and clinical pharmacology and co-director of the Auckland Cancer Society Research Centre at the university of Auckland, New Zealand. His current research focuses on how membrane transporters determine response and handling of platinum-based anticancer drugs. In addition, he leads a programme of phase I oncology trials at his centre.

"BMC Cancer is the leading Open Access international journal in the field of oncology. By publishing over 500 articles per year, BMC Cancer offers rapid dissemination of the most recent information of interest to the broad oncology science community."

Prof McKeage is the Section Editor of the Clinical oncology- medical oncology and pharmacology section of BMC Cancer.

Submit a manuscript Sign up for article alerts Contact us

Email updates

Receive periodic news and updates relating to BioMed Central straight to your inbox.

Indexed by

  • CAS
  • Cases Database
  • DOAJ
  • Embase
  • MEDLINE
  • PubMed
  • Science Citation Index Expanded
  • Scopus

View all

ISSN: 1471-2407